Roth Mkm Initiates Coverage on TriSalus Life Sciences (NASDAQ:TLSI)

Equities research analysts at Roth Mkm began coverage on shares of TriSalus Life Sciences (NASDAQ:TLSI) in a research report issued on Monday, Marketbeat.com reports. The firm set a “buy” rating and a $11.00 price target on the stock. Roth Mkm’s price target would suggest a potential upside of 146.64% from the company’s current price.

Other equities research analysts have also recently issued research reports about the company. Oppenheimer began coverage on TriSalus Life Sciences in a research note on Monday, September 16th. They set an “outperform” rating and a $10.00 price objective on the stock. Northland Securities assumed coverage on shares of TriSalus Life Sciences in a report on Friday, October 25th. They set an “outperform” rating and a $12.50 target price on the stock. Finally, Northland Capmk upgraded shares of TriSalus Life Sciences to a “strong-buy” rating in a research note on Friday, October 25th. Six analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $12.25.

TriSalus Life Sciences Price Performance

Shares of NASDAQ:TLSI opened at $4.46 on Monday. The company’s 50-day moving average price is $4.40 and its two-hundred day moving average price is $5.90. TriSalus Life Sciences has a one year low of $3.32 and a one year high of $10.42. The stock has a market capitalization of $135.99 million, a PE ratio of -1.79 and a beta of 0.49.

TriSalus Life Sciences (NASDAQ:TLSI) last released its earnings results on Wednesday, August 14th. The company reported ($0.21) earnings per share (EPS) for the quarter. The company had revenue of $7.36 million during the quarter. On average, analysts anticipate that TriSalus Life Sciences will post -1.51 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, CEO Mary T. Szela acquired 7,520 shares of the company’s stock in a transaction dated Thursday, September 12th. The shares were bought at an average cost of $5.20 per share, with a total value of $39,104.00. Following the completion of the transaction, the chief executive officer now directly owns 377,382 shares of the company’s stock, valued at $1,962,386.40. This trade represents a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is accessible through the SEC website. Company insiders own 32.80% of the company’s stock.

Hedge Funds Weigh In On TriSalus Life Sciences

Institutional investors and hedge funds have recently made changes to their positions in the company. Wolverine Asset Management LLC acquired a new stake in TriSalus Life Sciences during the 2nd quarter worth approximately $240,000. Highbridge Capital Management LLC bought a new position in TriSalus Life Sciences during the 2nd quarter worth $1,184,000. Finally, Duquesne Family Office LLC lifted its holdings in shares of TriSalus Life Sciences by 35.1% during the second quarter. Duquesne Family Office LLC now owns 426,921 shares of the company’s stock worth $2,357,000 after buying an additional 110,966 shares in the last quarter. Institutional investors and hedge funds own 2.58% of the company’s stock.

About TriSalus Life Sciences

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.